XELJANZ TABLETS 5 MG SPECIAL INVESTIGATION (INVESTIGATION OF LONG-TERM USE IN PATIENTS WITH ULCERATIVE COLITIS)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Jun 2019 Planned End Date changed from 25 Feb 2022 to 4 Jan 2022.
- 09 Jun 2019 Planned primary completion date changed from 25 Feb 2022 to 4 Jan 2022.
- 24 Apr 2019 Status changed from recruiting to active, no longer recruiting.